Survival of patients with KRAS G12C mutated stage IV non-small cell lung cancer with and without brain metastases treated with immune checkpoint inhibitors-Reference-Cited by-同舟云学术

Survival of patients with KRAS G12C mutated stage IV non-small cell lung cancer with and without brain metastases treated with immune checkpoint inhibitors

Published:2023-08 Issue: Volume:182 Page:107290
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Swart Esther M.,Noordhof Anneloes L.,Damhuis Ronald A.M.,Kunst Peter W.A.,De Ruysscher Dirk K.M.,Hendriks Lizza E.L.,van Geffen Wouter H.,Aarts Mieke J.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference54 articles.

1. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer;Borghaei;N. Engl. J. Med.,2015

2. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer;Brahmer;N. Engl. J. Med.,2015

3. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

4. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer;Reck;N. Engl. J. Med.,2016

5. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial;Rittmeyer;Lancet,2017

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Brain Metastases as Inaugural Sign of Non-Small Cell Lung Carcinoma: Case Series and Review of Literature;Cancers;2024-09-08

2. PD-1/PD-L1 Inhibitors for the Treatment of Lung Cancer;Immunotherapy Against Lung Cancer;2024